Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent

J.C. Sousa¹, R.T. Germano², C.C.M. Castro³, S.M.M. Magalhaes⁴ and R.F. Pinheiro¹,³

¹Programa de Pós-Graduação em Ciências Médicas, Departamento de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil
²Universidade Estadual do Ceará, Fortaleza, CE, Brasil
³Departamento de Patologia, Universidade Federal do Ceará, Fortaleza, CE, Brasil

Corresponding author: R.F. Pinheiro
E-mail: ronaldpinheiro@pq.cnpq.br

Received November 8, 2011
Accepted March 27, 2012
Published August 6, 2012
DOI http://dx.doi.org/10.4238/2012.August.6.8

ABSTRACT. Isochromosome 17q is a relatively common karyotypic abnormality in medulloblastoma, gastric, bladder, and breast cancers. In myeloid disorders, it is observed during disease progression and evolution to acute myeloid leukemia in Philadelphia-positive chronic myeloid leukemia. It has been reported in rare cases of myelodysplastic syndrome, with an incidence of 0.4-1.57%. Two new agents have been approved for treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia. These are the hypomethylating agents, 5-azacytidine and decitabine, recommended by consensus guidelines for high-risk myelodysplastic syndrome patients not eligible for
hematopoietic stem cell transplantation. We present a case of chronic myelomonocytic leukemia with normal cytogenetics at diagnosis treated with decitabine (with good response); however, the patient evolved to acute myeloid leukemia with i(17q) shortly after suspending treatment. To the best of our knowledge, this is the first report of acute myeloid leukemia with myelodysplasia-related changes with i(17q) after the use of a hypomethylating agent.

Key words: Myelodysplastic syndromes; Isochromosome 17q; Hypomethylation therapy

INTRODUCTION

Isochromosome 17q [i(17q)] is a relatively common karyotypic abnormality in medulloblastoma and gastric, bladder, and breast cancers. In myeloid disorders, it is observed during disease progression and evolution to acute myeloid leukemia (AML) in Philadelphia-positive chronic myeloid leukemia (Mitelman, 1995). It has been reported in rare cases of myelodysplastic syndrome (MDS), with an incidence of 0.4-1.57% (Marisavljevic et al., 2004). The appropriate categorization of hematological neoplasms associated with isolated i(17q) is uncertain. A proportion of cases would be more appropriately categorized as MDS/myeloproliferative neoplasm (MPN), unclassified.

Defined by the World Health Organization in 2008, AML with myelodysplasia-related changes is a new category of AML that includes a previous myelodysplastic phase or MDS/myeloproliferative phase (Brunning et al., 2008). Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic neoplasia characterized by features of both MPN and MDS (Brunning et al., 2008).

In 2006, we reported an 81-year-old man with MDS (refractory anemia with excess blasts II) who displayed a bone marrow G-banded karyotype: 46,XY,del(7)(q32),i(17)(q10). This report was the first of i(17q) plus the deletion of 7q in MDS. The patient became dependent on red blood cell (RBC) transfusions, and the disease transformed into AML 18 months later. The patient died 22 months after diagnosis (Pinheiro et al., 2006). This patient presented the features seen in previously reported patients: male, advanced age, severe anemia, hypercellular bone marrow, eosinophilia, basophilia, and increased micromegakaryocytes (Marisavljevic et al., 2004; Pinheiro et al., 2006). Most important, all of these cases were associated with a grim prognosis.

Therapeutic approaches to MDS/CMML should be based on the specific clinical features and risk stratification of each patient. Two new hypomethylating agents, 5-azacytidine and decitabine, have recently been approved for the treatment of MDS/CMML and are recommended by consensus guidelines for higher risk MDS patients who are ineligible for hematopoietic stem cell transplantation (NCCN, 2011).

The aim of this report is to present a case of CMML with normal cytogenetics at diagnosis that evolved into AML with i(17q) shortly after stopping treatment with decitabine (with significant response). We also review literature reports of AML with myelodysplasia-related changes with i(17q). To the best of our knowledge, this report is the first of AML with myelodysplasia-related changes with i(17q) after the use of a hypomethylating agent.
MATERIAL AND METHODS

Case report

A 57-year-old man was diagnosed with CMML in 2007. Peripheral blood tests at presentation gave the following results: hemoglobin = 13.4 g/dL; leukocytes = 24,400/µL; monocytes = 2684/µL, and platelets = 54 x 10^9/L. Bone marrow cytogenetics presented 46,XY[20]. According to the World Health Organization classification, CMML is considered a myelodysplastic/myeloproliferative neoplasm. Twenty-four months later, after short-term treatment with hydroxyurea, blood tests gave the following results: hemoglobin = 9.9 g/dL; leukocytes = 29,700/µL; monocytes = 1458/µL, and platelets = 12 x 10^9/L. Recombinant erythropoietin was initiated with no response, and the patient became dependent on RBC and platelet transfusions. At this time, cytogenetic analysis showed 46,XY[20]. Decitabine was started at 20 mg/m² per day for 5 days of a 6-week cycle. Severe febrile neutropenia developed after the third cycle, and treatment was delayed. By the fourth cycle, the patient showed progressive hematological improvement characterized by RBC transfusion independence and higher platelet count. The patient decided to discontinue treatment after 9 cycles. Six months later, the patient reported fatigue. The results of repeated bone marrow aspiration were compatible with AML with myelodysplasia-related changes, and cytogenetic analysis revealed 46,XY,i(17q)[20] (Figure 1). The patient died of sepsis shortly thereafter.

Figure 1. Karyotype from a patient with chronic myelomonocytic leukemia (CMML) treated with decitabine showing an i(17q) shortly after stopping treatment.
RESULTS AND DISCUSSION

i(17q) is a marker of unfavorable prognosis in myeloid disorders (Marisavljevic et al., 2004; Pinheiro et al., 2006). It has been reported most commonly during AML transformation of typical or atypical chronic myeloid leukemia (CML). These cases always show the same features: adult patient, mixed chronic myeloproliferative-myelodysplastic features, severe hyposegmentation of neutrophil nuclei, high risk for progression to AML (64% transformed), and median survival of 2.5 years (Marisavljevic et al., 2004; Pinheiro et al., 2006).

The case presented herein is a CMML patient who showed an excellent response to a hypomethylating agent (decitabine). The patient showed progressive hematological improvement characterized by RBC transfusion independence and higher platelet count. These changes were characterized as a complete response to decitabine during which the patient presented a normal karyotype. Disease progression occurred in a stepwise fashion resulting from the accumulation of genetic lesions that ultimately predisposed to genomic instability. In MDS and secondary AML patients, an extensive aberrant DNA methylation involving thousands of genes is observed compared with normal CD34(+) bone marrow cells or de novo AML blasts (Shen et al., 2010). Methylation, therefore, seems to increase as disease progresses from lower to higher risk status (Shen et al., 2010). The patient reported herein showed significant hematological response to decitabine by cycle 4 and experienced relapse once therapy was stopped, corroborating the hypothesis that hypermethylation is an acting phenomenon in MDS-associated physiopathologic processes. In addition, the karyotype during transformation presented i(17q), a marker of unfavorable prognosis.

To the best of our knowledge, this report is the first of i(17q) after the use of a hypomethylating agent for the treatment of MDS/MPN. Another very important marker of this case is the diagnosis of AML with myelodysplasia-related changes (a disorder associated with a grim prognosis).

We performed a systematic search of the medical literature for studies evaluating i(17q) in MDS/MPN between 1985 and 2011 using the PubMed database. The search was conducted using the following combination of key words: myelodysplastic or myelodysplasia and i(17q); myeloproliferative and i(17q); acute myeloid leukemia and i(17q); decitabine and i(17q), and hypomethylating therapy and i(17q). The principal objective was to find reports of patients who presented i(17q) during AML transformation secondary to MDS/MPN disorder. We reviewed cases of AML transformation secondary to MDS/MPN disorder with i(17q). These cases are listed in Table 1.

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Disease at diagnosis/No. cases</th>
<th>Karyotype at AML transformation</th>
<th>Prognosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Goh and Rubins, 1985</td>
<td>CML Ph-2 cases</td>
<td>i(17q), i(17q), + 13</td>
<td>Unfavorable</td>
</tr>
<tr>
<td>Fioretos et al., 1999</td>
<td>CML/8 cases</td>
<td>i(17q)</td>
<td>Unfavorable</td>
</tr>
<tr>
<td>Oren et al., 1999</td>
<td>CML/1 case pediatric</td>
<td>i(17q)</td>
<td>Unfavorable</td>
</tr>
<tr>
<td>Hernández-Boluda et al., 2000</td>
<td>CML/12 cases</td>
<td>i(17q)</td>
<td>Unfavorable</td>
</tr>
<tr>
<td>Mihrara et al., 2007</td>
<td>MPD/MPD 1 case</td>
<td>i(17q)</td>
<td>Unfavorable</td>
</tr>
<tr>
<td>Nishida et al., 2008</td>
<td>MPD/MPD/1 case</td>
<td>i(17q), + 14</td>
<td>Unfavorable</td>
</tr>
<tr>
<td>Park et al., 2009</td>
<td>MDS/1 case</td>
<td>i(17q)</td>
<td>Unfavorable</td>
</tr>
</tbody>
</table>

Table 1. Cases of i(17q) during acute myeloid leukemia (AML) transformation secondary to myelodysplastic syndrome/myeloproliferative neoplasia (MDS/MPN).

CML = chronic myeloid leukemia; MPD = myeloproliferative disorder.
Goh and Rubins (1985) have reported an isochromosome of the long arm of chromosome 17 in 2 patients diagnosed initially with Philadelphia-negative CML. At the time of AML transformation, one of the patients presented trisomy 13 in addition to i(17q). Both patients had a grim prognosis. Fioretos et al. (1999) described 21 cases of i(17q) among myeloid disorders, but only 8 were AML secondary to CML in blast crisis. The cases were associated with short survival. Oren et al. (1999) have reported a case of acute promyelocytic leukemia with i(17q) after BCR/ABL-positive CML. The case was a pediatric patient with i(17q) after 3.5 years of treatment for BCR/ABL-positive CML. Hernández-Boluda et al. (2000) have described 12 cases of i(17q) during blast crisis in Philadelphia-positive CML. All of these patients presented features of myeloproliferative disorder with short survival of only 22 months, and all of these cases are of AML transformation secondary to CML with unfavorable prognosis. The case we report herein is the first of AML transformation with i(17q) secondary to CMML, a clonal hematopoietic neoplasm characterized by persistent peripheral blood monocytosis (>1,000/mm$^3$) and no Philadelphia or BCR-ABL1 fusion. Of utmost importance, the patient in our current report presented i(17q) only after stopping the hypomethylating agent.

Mihara et al. (2007) have described a 69-year-old man with AML and an isolated i(17q) karyotypic abnormality who transformed from MPD/MDS. The patient was treated with anti-leukemic drugs including anthracyclines that controlled the disease for only 6 months. Nishida et al. (2008) have reported a similar case of i(17q) in a patient with leukemic transformation from MDS/MPD.

Park et al. (2009) have recently described a case of concomitant i(17q) and trisomy 14 in a patient with MDS in leukemic transformation. The patient was a 66-year-old Korean man with very poor prognosis. Kim et al. (2010) have also shown a case of i(17q) associated with other abnormalities. The patient had acute promyelocytic leukemia with t(15;17) (q22;q21) rearrangement combined with ider(17), but notably, this case was not one of AML with myelodysplasia-related changes.

We report the first case of i(17q) after the use of a hypomethylating agent for the treatment of MDS/MPN. Decitabine (5-aza-2'-deoxycytidine) is a cytosine nucleoside analog that, once incorporated into DNA, acts as a DNA methyltransferase inhibitor, reversing aberrant hypermethylation known to silence a variety of genes, including tumor suppressor genes (Shen et al., 2010). We do not know the real prognosis of i(17q) after stopping these drugs, but we speculate that it is as grim as that for patients who transform from CML. New reports are necessary to confirm this finding.

ACKNOWLEDGMENTS

Research supported by CAPES, CNPq, and FUNCAP.

REFERENCES


